Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-08-2023 | Osimertinib | Case report

Aumolertinib/osimertinib

Acquired drug resistance: 10 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Ding J, et al. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study. Frontiers in Oncology 13: 9 Jun 2023. Available from: URL: http://doi.org/10.3389/fonc.2023.1153131 Ding J, et al. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study. Frontiers in Oncology 13: 9 Jun 2023. Available from: URL: http://​doi.​org/​10.​3389/​fonc.​2023.​1153131
Metadata
Title
Aumolertinib/osimertinib
Acquired drug resistance: 10 case reports
Publication date
01-08-2023
Publisher
Springer International Publishing
Keyword
Osimertinib
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-44223-4

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Adalimumab

Case report

Multiple drugs

Case report

Trastuzumab